Non‐small cell lung cancer in China

P Chen, Y Liu, Y Wen, C Zhou - Cancer Communications, 2022 - Wiley Online Library
In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Current advance of nanotechnology in diagnosis and treatment for malignant tumors

B Wang, S Hu, Y Teng, J Chen, H Wang, Y Xu… - … and Targeted Therapy, 2024 - nature.com
Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary
field that is garnering a lot of interest and investigation. Nanomedicine shows great potential …

Management of stage III non–small-cell lung cancer: ASCO guideline

ME Daly, N Singh, N Ismaila, MB Antonoff… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in …

Q Zhou, M Chen, O Jiang, Y Pan, D Hu, Q Lin… - The Lancet …, 2022 - thelancet.com
Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer: the phase 2 KEYNOTE …

SK Jabbour, KH Lee, N Frost, V Breder… - JAMA …, 2021 - jamanetwork.com
Importance Administration of pembrolizumab plus concurrent chemoradiation therapy
(cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small …

Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review

KC Arbour, GJ Riely - Jama, 2019 - jamanetwork.com
Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …

The biology and management of non-small cell lung cancer

RS Herbst, D Morgensztern, C Boshoff - Nature, 2018 - nature.com
Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

Radiotherapy toxicity

D De Ruysscher, G Niedermann, NG Burnet… - Nature reviews Disease …, 2019 - nature.com
Radiotherapy is used in> 50% of patients with cancer, both for curative and palliative
purposes. Radiotherapy uses ionizing radiation to target and kill tumour tissue, but normal …

Lung cancer: current therapies and new targeted treatments

FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon… - The Lancet, 2017 - thelancet.com
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Emerging nanotechnology and advanced materials for cancer radiation therapy

G Song, L Cheng, Y Chao, K Yang, Z Liu - Advanced materials, 2017 - Wiley Online Library
Radiation therapy (RT) including external beam radiotherapy (EBRT) and internal
radioisotope therapy (RIT) has been widely used for clinical cancer treatment. However …